This study confirmed through the mouse orthotopic NSCLC model that compared with Bevacizumab alone, the combination of BMI1 inhibitor PTC-209 and Bevacizumab showed better tumor suppression effect. Here, BMI1 is linked to non-small cell lung carcinoma.